Cidofovir sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412889

CAS#: 127749-27-3 (Na)

Description: Cidofovir sodium is the salt form of Cidofovir, a Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor that is an injectable antiviral medication primarily used as a treatment for cytomegalovirus (CMV) retinitis in people with AIDS. The mechanism of action of cidofovir is as a DNA Polymerase Inhibitor. The chemical classification of cidofovir anhydrous is Nucleoside Analog.

Chemical Structure

img
Cidofovir sodium
CAS# 127749-27-3 (Na)
Instruction

Theoretical Analysis

MedKoo Cat#: 412889
Name: Cidofovir sodium
CAS#: 127749-27-3 (Na)
Chemical Formula: C8H12N3Na2O6P
Exact Mass: 0.00
Molecular Weight: 323.152
Elemental Analysis: C, 29.73; H, 3.74; N, 13.00; Na, 14.23; O, 29.71; P, 9.58

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 149394-66-1 (hydrate)   127749-27-3 (Na)   113852-37-2 (free base)  

Synonym: Cidofovir sodium; Cidofovir disodium; UNII-M83JB37U61

IUPAC/Chemical Name: sodium (S)-(((1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonate

InChi Key: HKIAHFPOQYDOHP-ILKKLZGPSA-L

InChi Code: InChI=1S/C8H14N3O6P.2Na/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16;;/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16);;/q;2*+1/p-2/t6-;;/m0../s1

SMILES Code: NC1=NC(N(C=C1)C[C@H](OCP([O-])([O-])=O)CO)=O.[Na+].[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 323.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ison MG, Hayden RT. Adenovirus. Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.DMIH2-0020-2015. PMID: 27726766.

2: Alcamo AM, Wolf MS, Alessi LJ, Chong HJ, Green M, Williams JV, Simon DW. Successful Use of Cidofovir in an Immunocompetent Child With Severe Adenoviral Sepsis. Pediatrics. 2020 Jan;145(1):e20191632. doi: 10.1542/peds.2019-1632. Epub 2019 Dec 11. PMID: 31826930; PMCID: PMC6939840.

3: Lynch JP 3rd, Fishbein M, Echavarria M. Adenovirus. Semin Respir Crit Care Med. 2011 Aug;32(4):494-511. doi: 10.1055/s-0031-1283287. Epub 2011 Aug 19. PMID: 21858752.

4: Lynch JP 3rd, Kajon AE. Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention. Semin Respir Crit Care Med. 2016 Aug;37(4):586-602. doi: 10.1055/s-0036-1584923. Epub 2016 Aug 3. PMID: 27486739; PMCID: PMC7171713.

5: Meesing A, Razonable RR. New Developments in the Management of Cytomegalovirus Infection After Transplantation. Drugs. 2018 Jul;78(11):1085-1103. doi: 10.1007/s40265-018-0943-1. PMID: 29961185.

6: Mühlbacher T, Beck R, Nadalin S, Heyne N, Guthoff M. Low-dose cidofovir and conversion to mTOR-based immunosuppression in polyomavirus-associated nephropathy. Transpl Infect Dis. 2020 Apr;22(2):e13228. doi: 10.1111/tid.13228. Epub 2019 Dec 16. PMID: 31797495.

7: Nickles MA, Sergeyenko A, Bain M. Treatment of warts with topical cidofovir in a pediatric patient. Dermatol Online J. 2019 May 15;25(5):13030/qt5sq5b24g. PMID: 31220896.

8: Greeley ZW, Giannasca NJ, Porter MJ, Margulies BJ. Acyclovir, cidofovir, and amenamevir have additive antiviral effects on herpes simplex virus TYPE 1. Antiviral Res. 2020 Apr;176:104754. doi: 10.1016/j.antiviral.2020.104754. Epub 2020 Feb 27. PMID: 32114034.

9: Lea AP, Bryson HM. Cidofovir. Drugs. 1996 Aug;52(2):225-230; discussion 231. doi: 10.2165/00003495-199652020-00006. PMID: 8841740.

10: Gerna G, Lilleri D, Baldanti F. An overview of letermovir: a cytomegalovirus prophylactic option. Expert Opin Pharmacother. 2019 Aug;20(12):1429-1438. doi: 10.1080/14656566.2019.1637418. Epub 2019 Jul 8. PMID: 31282759.